Literature DB >> 2656051

Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

H G Shetty1, A G Fennerty, P A Routledge.   

Abstract

Aspects of the pharmacokinetics of warfarin that are clinically relevant are reviewed here. Since warfarin is normally completely absorbed, resistance to treatment due to impaired absorption is unusual, even in severe short bowel syndrome. Warfarin is highly albumin-bound; thus, hypoalbuminaemic states result in an increased free fraction of the drug and a decreased half-life but, as might be expected, there is no evidence of altered response at steady-state. Warfarin is completely metabolised by the liver to hydroxy-warfarins and warfarin alcohols, and although the latter have some biological activity they do not contribute significantly to the drug effect. No information is available concerning the metabolism of warfarin in chronic liver disease, but there is evidence of increased sensitivity due to impaired vitamin K-dependent clotting factor synthesis. Impaired renal function does not appear to alter the effect of warfarin. Lowered response to the drug may be secondary to poor compliance, kinetic resistance or pharmacodynamic resistance. These factors can be identified using algorithms based on population values for plasma warfarin concentrations and clearances at steady-state. The pharmacokinetics and pharmacodynamics of warfarin indicate that several days' overlap with heparin on initiation of warfarin, and gradual (rather than sudden) discontinuation of warfarin, might theoretically be necessary. However, those studies which have been performed have indicated that a long overlap and gradual discontinuation are not associated with greater safety or efficacy of the drug. Because of the long elimination half-life of warfarin and the short elimination half-life of vitamin K, many days' treatment with phytomenadione may be required after warfarin overdose. The elimination half-life and therefore the duration of therapy may be reduced by regular oral cholestyramine, although the means by which the latter enhances warfarin elimination is still unknown.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2656051     DOI: 10.2165/00003088-198916040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  76 in total

1.  Coagulation components in normal and abnormal pregnancies.

Authors:  O D RATNOFF; T R HOLLAND
Journal:  Ann N Y Acad Sci       Date:  1959-01-09       Impact factor: 5.691

2.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

3.  Genetic control of dicumarol levels in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

4.  Thromboembolic complications during anticoagulant therapy.

Authors:  W W Coon; P W Willis
Journal:  Arch Surg       Date:  1972-08

5.  Vitamin K in hereditary resistance to oral anticoagulant drugs.

Authors:  R A O'Reilly
Journal:  Am J Physiol       Date:  1971-11

6.  "Resistance" to warfarin due to unrecognized vitamin K supplementation.

Authors:  R A O'Reilly; D A Rytand
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

7.  Kinetics of R andS warfarin enantiomers.

Authors:  C Hignite; J Uetrecht; C Tschanz; D Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

8.  Inhibition of vitamin K-dependent carboxylase in vitro by cefamandole and its structural analogs.

Authors:  L Uotila; J W Suttie
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

9.  Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.

Authors:  R L Williams; W L Schary; T F Blaschke; P J Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

10.  Lack of effect of fortified wine ingested during fasting and anticoagulant therapy.

Authors:  R A O'Reilly
Journal:  Arch Intern Med       Date:  1981-03
View more
  10 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 4.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

5.  Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers.

Authors:  W Couet; B Istin; J P Decourt; I Ingrand; J Girault; J B Fourtillan
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 6.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

7.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.

Authors:  E Chan; A J McLachlan; M Pegg; A D MacKay; R B Cole; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 8.  Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.

Authors:  Freek W A Verheugt
Journal:  Clin Cardiol       Date:  2013-04-08       Impact factor: 2.882

Review 9.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

10.  Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data.

Authors:  Zhi Zhou; Ikuko Yano; Sumiko Odaka; Yosuke Morita; Satoshi Shizuta; Mamoru Hayano; Takeshi Kimura; Akinori Akaike; Ken-Ichi Inui; Kazuo Matsubara
Journal:  J Pharm Health Care Sci       Date:  2016-08-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.